September 19.th Øystein Rekdal was invited as guest speaker at Karolinska Institutet (KI) in Stockholm, Sweden. The title on his lecture was "The oncolytic peptide LTX-315 represents a novel immunotherapeutic strategy".

Rekdal received good response from the immunoncology research mileu at KI.